BioNote (KRX:377740) posted first-quarter net income attributable to shareholders of 41.3 billion won, up 925% from 4.03 billion won a year earlier, according to a Wednesday filing with the Korea Exchange.
The South Korean biotechnology and diagnostics company's sales rose 15% year over year to 32.6 billion won from 28.5 billion won.
Shares of BioNote rose more than 3% in recent trade.